1-13 of 13
Miriam Y Kim
Close
Sort by
Journal Articles

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

Jingyu Xiang, Jessica Devenport, Alun J Carter, Karl Staser, Michael P. Rettig, Miriam Y Kim, Julie O'Neal, Julie K. Ritchey, Feng Gao, Garrett Rettig, Rolf Turk, Alexandra Wolfarth, Byung Ha Lee, Matthew L. Cooper, John F. DiPersio
Journal: Blood
Blood (2023) 142 (Supplement 1): 764.
https://doi.org/10.1182/blood-2023-181087
Published: 2023
Journal Articles

Targeting Normal Myelopoiesis Negatively Affects CAR T Cell Activity

Miriam Y Kim, Matthew L. Cooper, Julie K. Ritchey, Julie O'Neal, John DiPersio
Journal: Blood
Blood (2023) 142 (Supplement 1): 2077.
https://doi.org/10.1182/blood-2023-186015
Published: 2023
Journal Articles

CXCR4 to improve both T cell homing and function

Miriam Y. Kim
Journal: Blood
Blood (2023) 141 (21): 2546–2547.
https://doi.org/10.1182/blood.2023020050
Published: 2023
Journal Articles

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells

Brief Report
Joseph C. Rimando, Ezhilarasi Chendamarai, Michael P. Rettig, Reyka Jayasinghe, Matthew J. Christopher, Julie K. Ritchey, Stephanie Christ, Miriam Y. Kim, Ezio Bonvini, John F. DiPersio
Journal: Blood
Blood (2023) 141 (14): 1718–1723.
https://doi.org/10.1182/blood.2022017795
Published: 2023
Includes: Supplemental data
Journal Articles

Normal Myeloid Cells Are Required for Sustained CAR T Cell Activity Against Myeloid Tumor in a Humanized Mouse Model

Miriam Y Kim, Matthew L Cooper, Julie K Ritchey, Julia Hollaway, John F. DiPersio
Journal: Blood
Blood (2021) 138 (Supplement 1): 734.
https://doi.org/10.1182/blood-2021-150935
Published: 2021
Journal Articles

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Margery Gang, Nancy D. Marin, Pamela Wong, Carly C. Neal, Lynne Marsala, Mark Foster, Timothy Schappe, Wei Meng, Jennifer Tran, Maximilian Schaettler, Marco Davila, Feng Gao, Amanda F. Cashen, Nancy L. Bartlett, Neha Mehta-Shah, Brad S. Kahl, Miriam Y. Kim, Matthew L. Cooper, John F. DiPersio, Melissa M. Berrien-Elliott, Todd A. Fehniger
Journal: Blood
Blood (2020) 136 (20): 2308–2318.
https://doi.org/10.1182/blood.2020006619
Published: 2020
Includes: Supplemental data
Journal Articles

Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo

Joseph Rimando, MD, Michael P. Rettig, PhD, Matt Christopher, MD PhD, Julie K Ritchey, Miriam Y Kim, MD, John Muth, MS, Jan Davidson, John F. DiPersio, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-133891
Published: 2020
Journal Articles

Chimeric Antigen Receptor T Cells Specific for CLL-1 for Treatment of Acute Myeloid Leukemia

Elisa De Togni, BA, Miriam Y Kim, MD, Matt L Cooper, PhD, Julie Ritchey, Julie O'Neal, PhD, Jessica Niswonger, John F. DiPersio, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2205.
https://doi.org/10.1182/blood-2018-99-113438
Published: 2018
Journal Articles

Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia

Miriam Y Kim, MD, Saad S Kenderian, MD, Daniel Schreeder, MD PhD, Michael Klichinsky, PharmD, Miroslaw Kozlowski, PhD, Olga Shestova, PhD, Marco Ruella, MD, Saar I Gill, MBBS, PhD
Journal: Blood
Blood (2016) 128 (22): 1000.
https://doi.org/10.1182/blood.V128.22.1000.1000
Published: 2016
Journal Articles

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, Craig Soderquist, MD, Adam Bagg, MD, Reshma Singh, PhD, Celeste Richardson, PhD, Regina M Young, PhD, Carl H June, MD, Saar I. Gill, MD PhD
Journal: Blood
Blood (2016) 128 (22): 766.
https://doi.org/10.1182/blood.V128.22.766.766
Published: 2016
Journal Articles

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Miriam Y Kim, MD, Michael Klichinsky, PharmD, Fang Chen, PhD, Natalka Kengle, Simon Francis Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Saar I. Gill, MD PhD
Journal: Blood
Blood (2016) 128 (22): 652.
https://doi.org/10.1182/blood.V128.22.652.652
Published: 2016
Journal Articles

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, David L Porter, MD, Carl H. June, MD, Saar I Gill, MBBS, PhD
Journal: Blood
Blood (2015) 126 (23): 852.
https://doi.org/10.1182/blood.V126.23.852.852
Published: 2015
Journal Articles

Outcome Disparities In Waldenstrom's Macroglobulinemia: A SEER Database Analysis

Sikander Ailawadhi, MD, Dongyun Yang, PhD, Gaurav Patel, MSHA, Yin Zhang, MD, Ibrahim T. Aldoss, MBBS, Miriam Y. Kim, MD, Asher Chanan-Khan, MD
Journal: Blood
Blood (2011) 118 (21): 845.
https://doi.org/10.1182/blood.V118.21.845.845
Published: 2011